An Observational Study of Nivolumab (ONO-4538) for cancer of unknown primary (CUP) (NivoCUP-2F, WJOG14620MFS)

An Observational Study of Nivolumab (ONO-4538) for cancer of unknown primary (CUP) (NivoCUP-2F, WJOG14620MFS) - WJOG14620MFS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046500

Enrollment

Registered

2022-01-01

Start date

2022-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of unknown primary

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Subjects who were enrolled WJOG14620M -Subjects must have a signed and dated written informed consent form

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
To evaluate efficacy of nivolumab in patients enrolled in the "Nivolumab (ONO-4538) Expanded Multicenter Open-label, Uncontrolled Study for Primary Cancer of Unknown Origin" (WJOG14620M, NivoCUP2) by overall response rate, disease control rate, progression-free survival and overall survival	—

Countries

Japan

Contacts

Public ContactMitsuru Shimomura

West Japan Oncology Group West Japan Oncology Group

chiken@wjog.jp06-6633-7400

Outcome results